The history of Eukarÿs is closely tied to the C3P3 technology – our expression technology developed from scratch.

C3P3 is the first ever non-viral artificial eukaryotic expression system, which synthesize autonomously and at high yields the messenger RNA(s) of interest (mRNA) in the host cell cytoplasm, thereby leading to high production levels of the target protein(s).

The crucial role of mRNA in the flow of genetic information explains that the C3P3 system has a wide range of in vivo therapeutic and non-therapeutic applications in the entire eukaryotic world.

Until late 2000s, the development of an artificial eukaryotic expression system was nearly impossible due to the amazing complexity of eukaryotic post-transcriptional mRNA modifications.

The emergence of synthetic biology during the last decade was pivotal, allowing the construction of the C3P3 expression system (stands for chimeric cytoplasmic capping prone phage polymerase).

The development of the first generation of C3P3 (C3P3-G1) was completed early 2016 with good performances with CpG-free DNA templates, which are preferably used for our synthetic gene therapy – a novel therapeutic approach designed as safe, efficient and operating for most human disorders.

 

Eukarÿs is currently finalizing the third generation of its C3P3 system (C3P3-G3) with much greater complexity and performances than the initial prototype. C3P3-G3 is used for both synthetic gene therapy and bioproduction tools.

Today, Eukarÿs is a preclinical-stage biotechnology company aiming to extend its synthetic gene therapy approach to other therapeutic fields, such as deficiencies of secreted proteins, oncology and others. Eukarÿs exploits and license-out its C3P3 tools for the bioproduction of recombinant proteins and viruses bioproduction.